Fundz

Fundz Deep Dive

Everything you need to win Julie Bailey — in one platform.

Who to reach, what to say, and why now on Julie Bailey — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.

Get the full Deep Dive on Julie Bailey — free.

One free Deep Dive, emailed to you. No spam; unsubscribe anytime.

Ready now? Choose your plan · Request a demo · Sign in

Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.

Ilc Therapeutics Appoints Owain Millington As Chief Executive Officer, Julie Bailey As Chief Financial Officer, and Dawn Firmin As Chief Operations Officer

PRIVATESep 11, 2024•almost 2 years ago

Position

Chief Financial Officer

Company

Ilc Therapeutics

Julie Bailey
Glasgow

Description

ILC Therapeutics has successfully completed a fundraise of 2.5 million GBP and announced the appointments of Owain Millington as Chief Executive Officer, Julie Bailey as Chief Financial Officer, and Dawn Firmin as Chief Operations Officer with immediate effect.

Company Information

Company

Ilc Therapeutics

Location

Glasgow, Kentucky, United States

About

ILC Therapeutics Ltd is an emerging biotechnology company focused on modulating the innate immune system through the design and development of novel hybrid interferon drug candidates. Interferons are naturally produced chemical messenger molecules that ‘interfere’ with viral reproduction; they are the body’s first and most powerful defence against all viral pathogens. However, in many cases, and these include SARS, MERS and Covid-19, viruses evolve resistance mechanisms to evade or reduce natural interferon responses. ILCT’s Hybrid Interferons are designed by identifying selected favourable attributes of naturally occurring interferon subtypes and combining them together in a new class of novel Hybrid Interferons. ILC’s Hybrid Interferons will evade natural resistance and have the potential to provide enhanced efficacy and improved safety in comparison to the natural interferon subtypes. The company was founded by Prof. W. H. Stimson FRSE, who established the Department of Immunology at The University of Strathclyde.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for Ilc Therapeutics's next move

Learn about Strategic plan

Executive Insights

Based on hiring data
New executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.